Holen Sie sich die Stockscreener-App
1.90
4.40%
0.08
Handel nachbörslich:
1.90
Schlusskurs vom Vortag:
$1.82
Offen:
$1.8
24-Stunden-Volumen:
10,781
Relative Volume:
0.26
Marktkapitalisierung:
$69.92M
Einnahmen:
$24.38M
Nettoeinkommen (Verlust:
$-53.95M
KGV:
-0.7692
EPS:
-2.47
Netto-Cashflow:
$-23.31M
1W Leistung:
+5.56%
1M Leistung:
+1.06%
6M Leistung:
-56.72%
1J Leistung:
-44.12%
1-Tages-Spanne:
$1.7502
$1.95
1-Wochen-Bereich:
$1.72
$2.035
52-Wochen-Spanne:
$1.61
$5.24
Elutia Inc Stock (ELUT) Company Profile
Firmenname
Elutia Inc
Sektor
Branche
Telefon
240-247-1143
Adresse
12510 PROSPERITY DRIVE, SILVER SPRING
Vergleichen Sie ELUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.90 | 67.84M | 24.38M | -53.95M | -23.31M | -2.47 |
|
ABT
Abbott Laboratories
|
133.58 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-02 | Eingeleitet | Cowen | Outperform |
| 2020-11-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-11-02 | Eingeleitet | Truist | Buy |
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Elutia (NASDAQ:ELUT) Shares Down 1% – Time to Sell? - Defense World
Aziyo Biologics Holds Annual Stockholders Meeting - TipRanks
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET By Investing.com - Investing.com South Africa
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET - Investing.com
Elutia v. Medtronic: Delaware court rules on indemnity and insurance obligations in FiberCel lawsuit - Insurance Business America
ELUT stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
ELUT stock touches 52-week low at $1.61 amid market challenges - Investing.com Australia
Elutia Inc. Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method - marketscreener.com
Elutia announces publication of article on measuring antibiotic release - TipRanks
Elutia (ELUT) Innovates with New Antibiotic Release Method | ELUT Stock News - GuruFocus
Revolutionary Drug Testing Method Cuts Medical Device Development Time from 14 Days to Just 30 Hours - Stock Titan
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Aziyo Biologics (ELUT) Receives a New Rating from Lake Street - The Globe and Mail
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia to Participate in Chardan's Trending Issues in Drug Devel - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
Elutia unaffected by global tariffs, maintains US focus - Investing.com Canada
Elutia Unaffected by Global Tariffs Due to US-Based Operations - marketscreener.com
Finanzdaten der Elutia Inc-Aktie (ELUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elutia Inc-Aktie (ELUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HighCape Capital, L.P. | Director |
Feb 03 '25 |
Buy |
2.50 |
420,000 |
1,050,000 |
9,520,232 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Jul 31 '24 |
Option Exercise |
1.43 |
105,080 |
150,002 |
257,823 |
0.56%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):